Analysis of Key Genes and miRNA-mRNA Networks Associated with Glucocorticoids Treatment in Chronic Obstructive Pulmonary Disease

References

• Brightling C, Greening N. Airway Inflammation in COPD: progress to precision medicine. Eur Respir J. 2019;54(2):1900651. doi:10.1183/13993003.00651-2019
   PubMed Web of Science ®Google Scholar
• McGeachie MJ, Sordillo JE, Dahlin A, et al. Expression of SMARCD1 interacts with age in association with asthma control on inhaled corticosteroid therapy. Respir Res. 2020;21(1):31. doi:10.1186/s12931-020-1295-4
   PubMed Web of Science ®Google Scholar
• Navanandan N, Moran E, Smith H, Hoch H, Mistry RD. Primary care provider preferences for glucocorticoid management of acute asthma exacerbations in children. J Asthma. 2021;58(4):547–553. doi:10.1080/02770903.2019.1709869
   PubMed Web of Science ®Google Scholar
• Zheng J-P, Zhang J, Ma L-J, et al. Clinical outcomes of using nebulized budesonide as the initial treatment for acute exacerbations of chronic obstructive pulmonary disease: a Post-Hoc analysis. Int J Chron Obstruct Pulmon Dis. 2019;14:2725–2731. doi:10.2147/COPD.S196615
   PubMed Web of Science ®Google Scholar
• Zhang J, Zheng J, Huang K, Chen Y, Yang J, Yao W. Use of glucocorticoids in patients with COPD exacerbations in China: a retrospective observational study. Ther Adv Respir Dis. 2018;12:1753466618769514. doi:10.1177/1753466618769514
   Web of Science ®Google Scholar
• Chronic Obstructive Pulmonary Disease Group of Chinese Thoracic Society; Chronic Obstructive Pulmonary Disease Committee of Chinese Association of Chest Physician. 中华医学会呼吸病学分会慢性阻塞性肺疾病学组, 中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 慢性阻塞性肺疾病诊治指南(2021年修订版) [Guidelines for the diagnosis and management of chronic obstructive pulmonary disease (revised version 2021)]. Zhonghua Jie He He Hu Xi Za Zhi. 2021;44(3):170–205. Chinese. doi:10.3760/cma.j.cn112147-20210109-00031
   PubMedGoogle Scholar
• Nannini LJ, Poole P, Milan SJ, Holmes R, Normansell R. Combined corticosteroid and long-acting beta₂-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;2013(11):CD003794. doi:10.1002/14651858.CD003794.pub4
   PubMedGoogle Scholar
• Vestbo J, Leather D, Diar Bakerly N, et al. Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice. N Engl J Med. 2016;375(13):1253–1260. doi:10.1056/NEJMoa1608033
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa1713901
   PubMed Web of Science ®Google Scholar
• Sonnex K, Alleemudder H, Knaggs R. Impact of smoking status on the efficacy of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review. BMJ Open. 2020;10(4):e037509. doi:10.1136/bmjopen-2020-037509
   PubMed Web of Science ®Google Scholar
• Calverley PMA, Anderson JA, Brook RD, et al. Fluticasone furoate, vilanterol, and lung function decline in patients with moderate chronic obstructive pulmonary disease and heightened cardiovascular risk. Am J Respir Crit Care Med. 2018;197(1):47–55. doi:10.1164/rccm.201610-2086OC
   PubMed Web of Science ®Google Scholar
• 2023 GOLD Report. Available from: https://goldcopd.org/2023-gold-report-2/. Accessed August 31, 2023.
   Google Scholar
• Ding Z, Li X, Lu Y, et al. A randomized, controlled multicentric study of inhaled budesonide and intravenous methylprednisolone in the treatment on acute exacerbation of chronic obstructive pulmonary disease. Respir Med. 2016;121:39–47. doi:10.1016/j.rmed.2016.10.013
   PubMed Web of Science ®Google Scholar
• Sun X, He Z, Zhang J, et al. Compare the efficacy of inhaled budesonide and systemic methylprednisolone on systemic inflammation of AECOPD. Pulm Pharmacol Ther. 2015;31:111–116. doi:10.1016/j.pupt.2014.09.004
   PubMed Web of Science ®Google Scholar
• Pleasants RA, Wang T, Xu X, et al. Nebulized corticosteroids in the treatment of COPD exacerbations: systematic review, meta-analysis, and clinical perspective. Respir Care. 2018;63(10):1302–1310. doi:10.4187/respcare.06384
   PubMed Web of Science ®Google Scholar
• Reddy AT, Lakshmi SP, Banno A, Reddy RC. Glucocorticoid receptor α mediates Roflumilast’s ability to restore dexamethasone sensitivity in COPD. Int J Chron Obstruct Pulmon Dis. 2020;15:125–134. doi:10.2147/COPD.S230188
   PubMed Web of Science ®Google Scholar
• Ko FWS, Sin DD. Twenty-five years of respirology: advances in COPD. Respirology. 2020;25(1):17–19. doi:10.1111/resp.13734
   PubMed Web of Science ®Google Scholar
• Hodge G, Jersmann H, Tran HB, Holmes M, Reynolds PN, Hodge S. Lymphocyte senescence in COPD is associated with loss of glucocorticoid receptor expression by pro-inflammatory/cytotoxic lymphocytes. Respir Res. 2015;16(1):2. doi:10.1186/s12931-014-0161-7
   PubMedGoogle Scholar
• Wu J, Li X, Qin Y, et al. Jinwei Tang modulates HDAC2 expression in a rat model of COPD. Exp Ther Med. 2018;15(3):2604–2610. doi:10.3892/etm.2018.5707
   PubMed Web of Science ®Google Scholar
• Stolz D, Matera MG, Rogliani P, et al. Current and future developments in the pharmacology of asthma and COPD: ERS Seminar, Naples 2022. Breathe. 2023;19(2):220267. doi:10.1183/20734735.0267-2022
   Web of Science ®Google Scholar
• Mei D, Tan WSD, Wong WSF. Pharmacological strategies to regain steroid sensitivity in severe asthma and COPD. Curr Opin Pharmacol. 2019;46:73–81. doi:10.1016/j.coph.2019.04.010
   PubMed Web of Science ®Google Scholar
• Tang H, Mao J, Ye X, et al. SHIP-1, a target of miR-155, regulates endothelial cell responses in lung fibrosis. FASEB J. 2020;34(2):2011–2023. doi:10.1096/fj.201902063R
   PubMed Web of Science ®Google Scholar
• Hobbs BD, Tantisira KG. MicroRNAs in COPD: small molecules with big potential. Eur Respir J. 2019;53(4):1900515. doi:10.1183/13993003.00515-2019
   PubMed Web of Science ®Google Scholar
• Conickx G, Avila Cobos F, van den Berge M, et al. microRNA profiling in lung tissue and bronchoalveolar lavage of cigarette smoke-exposed mice and in COPD patients: a translational approach. Sci Rep. 2017;7(1):12871. doi:10.1038/s41598-017-13265-8
   PubMed Web of Science ®Google Scholar
• De Smet EG, Van Eeckhoutte HP, Avila Cobos F, et al. The role of miR-155 in cigarette smoke-induced pulmonary inflammation and COPD. Mucosal Immunol. 2020;13(3):423–436. doi:10.1038/s41385-019-0241-6
   PubMed Web of Science ®Google Scholar
• Zhuang Y, Hobbs BD, Hersh CP, Kechris K. Identifying miRNA-mRNA networks associated with COPD phenotypes. Front Genet. 2021;12:748356. doi:10.3389/fgene.2021.748356
   PubMed Web of Science ®Google Scholar
• Kaur G, Maremanda KP, Campos M, et al. Distinct exosomal miRNA profiles from BALF and lung tissue of COPD and IPF patients. Int J Mol Sci. 2021;22(21):11830. doi:10.3390/ijms222111830
   PubMed Web of Science ®Google Scholar
• Rojas-Quintero J, Polverino F. Tweaking lung inflammation in COPD: the “Mirky” ways of miRNAs. Am J Physiol Lung Cell Mol Physiol. 2021;321(6):L1089–L1090. doi:10.1152/ajplung.00435.2021
   PubMed Web of Science ®Google Scholar
• Climent M, Viggiani G, Chen Y-W, Coulis G, Castaldi A. MicroRNA and ROS crosstalk in cardiac and pulmonary diseases. Int J Mol Sci. 2020;21(12):4370. doi:10.3390/ijms21124370
   PubMed Web of Science ®Google Scholar
• Ma F, Liu F, Ding L, et al. Anti-Inflammatory effects of curcumin are associated with down regulating microRNA-155 in LPS-treated macrophages and mice. Pharm Biol. 2017;55(1):1263–1273. doi:10.1080/13880209.2017.1297838
   PubMed Web of Science ®Google Scholar
• Faiz A, Steiling K, Roffel MP, et al. Effect of long-term corticosteroid treatment on microRNA and gene-expression profiles in COPD. Eur Respir J. 2019;53(4):1801202. doi:10.1183/13993003.01202-2018
   PubMed Web of Science ®Google Scholar
• Sundar IK, Li D, Rahman I. Small RNA-sequence analysis of plasma-derived extracellular vesicle miRNAs in smokers and patients with chronic obstructive pulmonary disease as circulating biomarkers. J Extracell Vesicles. 2019;8(1):1684816. doi:10.1080/20013078.2019.1684816
   PubMed Web of Science ®Google Scholar
• Li J, Wang J, Li Y, et al. Effective-component compatibility of bufei yishen formula protects COPD rats against PM2.5-induced oxidative stress via miR-155/FOXO3a pathway. Ecotoxicol Environ Saf. 2021;228:112918. doi:10.1016/j.ecoenv.2021.112918
   PubMed Web of Science ®Google Scholar
• Zhou H, Li J, Gao P, Wang Q, Zhang J. miR-155: a novel target in allergic asthma. Int J Mol Sci. 2016;17(10):1773. doi:10.3390/ijms17101773
   PubMed Web of Science ®Google Scholar
• Reddy AT, Lakshmi SP, Banno A, Reddy RC. Role of GPx3 in PPARγ-induced protection against COPD-associated oxidative stress. Free Radic Biol Med. 2018;126:350–357. doi:10.1016/j.freeradbiomed.2018.08.014
   PubMed Web of Science ®Google Scholar
• Golpon HA, Coldren CD, Zamora MR, et al. Emphysema lung tissue gene expression profiling. Am J Respir Cell Mol Biol. 2004;31(6):595–600. doi:10.1165/rcmb.2004-0008OC
   PubMed Web of Science ®Google Scholar
• Ayroldi E, Riccardi C. Glucocorticoid-Induced Leucine Zipper (GILZ): a new important mediator of glucocorticoid action. FASEB J. 2009;23(11):3649–3658. doi:10.1096/fj.09-134684
   PubMed Web of Science ®Google Scholar
• Gałecka E, Kumor-Kisielewska A, Górski P. Association of serum deiodinase type 2 level with chronic obstructive pulmonary disease in the Polish Population. Acta Biochim Pol. 2019;66(2). doi:10.18388/abp.2018_2761
   PubMed Web of Science ®Google Scholar
• Hu Y, He T, Zhu J, et al. The link between circadian clock genes and autophagy in chronic obstructive pulmonary disease. Mediators Inflamm. 2021;2021:2689600. doi:10.1155/2021/2689600
   PubMed Web of Science ®Google Scholar
• Yao H, Sundar IK, Huang Y, et al. Disruption of Sirtuin 1-mediated control of circadian molecular clock and inflammation in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2015;53(6):782–792. doi:10.1165/rcmb.2014-0474OC
   PubMed Web of Science ®Google Scholar
• Kim RY, Oliver BG, Wark PAB, Hansbro PM, Donovan C. COPD Exacerbations: targeting IL-33 as a New Therapy. Lancet Respir Med. 2021;9(11):1213–1214. doi:10.1016/S2213-2600(21)00182-X
   PubMed Web of Science ®Google Scholar
• Plumb J, Robinson L, Lea S, et al. Evaluation of glucocorticoid receptor function in COPD lung macrophages using beclomethasone-17-monopropionate. PLoS One. 2013;8(5):e64257. doi:10.1371/journal.pone.0064257
   PubMed Web of Science ®Google Scholar
• Newton R. Anti-Inflammatory glucocorticoids: changing concepts. Eur J Pharmacol. 2014;724:231–236. doi:10.1016/j.ejphar.2013.05.035
   PubMed Web of Science ®Google Scholar
• Eddleston J, Herschbach J, Wagelie-Steffen AL, Christiansen SC, Zuraw BL. The anti-inflammatory effect of glucocorticoids is mediated by glucocorticoid-induced leucine zipper in epithelial cells. J Allergy Clin Immunol. 2007;119(1):115–122. doi:10.1016/j.jaci.2006.08.027
   PubMed Web of Science ®Google Scholar
• Drake LY, Prakash YS. Contributions of IL-33 in non-hematopoietic lung cells to obstructive lung disease. Front Immunol. 2020;11:1798. doi:10.3389/fimmu.2020.01798
   PubMed Web of Science ®Google Scholar
• Cazzola M, Ora J, Cavalli F, Rogliani P, Matera MG. An overview of the safety and efficacy of monoclonal antibodies for the chronic obstructive pulmonary disease. Biologics. 2021;15:363–374. doi:10.2147/BTT.S295409
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang J, Li J, et al. miR-320/ELF3 axis inhibits the progression of breast cancer via the PI3K/AKT pathway. Oncol Lett. 2020;19(4):3239–3248. doi:10.3892/ol.2020.11440
   PubMed Web of Science ®Google Scholar
• Wang K, Chen Y, Zhao Z, Feng M, Zhang S. Identification of potential core genes and miRNAs in testicular seminoma via bioinformatics analysis. Mol Med Rep. 2019;20(5):4013–4022. doi:10.3892/mmr.2019.10684
   PubMed Web of Science ®Google Scholar
• Liu J, Xing Y, Rong L. miR-181 regulates cisplatin-resistant non-small cell lung cancer via downregulation of autophagy through the PTEN/PI3K/AKT pathway. Oncol Rep. 2018;39(4):1631–1639. doi:10.3892/or.2018.6268
   PubMed Web of Science ®Google Scholar
• Rezaei T, Amini M, Hashemi ZS, et al. microRNA-181 serves as a dual-role regulator in the development of human cancers. Free Radic Biol Med. 2020;152:432–454. doi:10.1016/j.freeradbiomed.2019.12.043
   PubMed Web of Science ®Google Scholar
• Kim JR, Horton NC, Mathew SO, Mathew PA. CS1 (SLAMF7) inhibits production of proinflammatory cytokines by activated monocytes. Inflamm Res. 2013;62(8):765–772. doi:10.1007/s00011-013-0632-1
   PubMed Web of Science ®Google Scholar
• Gutierrez-Guerrero A, Mancilla-Herrera I, Maravillas-Montero JL, Martinez-Duncker I, Veillette A, Cruz-Munoz ME. SLAMF7 selectively favors degranulation to promote cytotoxicity in human NK cells. Eur J Immunol. 2022;52(1):62–74. doi:10.1002/eji.202149406
   PubMed Web of Science ®Google Scholar
• Tassi I, Colonna M. The cytotoxicity receptor CRACC (CS-1) recruits EAT-2 and activates the PI3K and phospholipase cgamma signaling pathways in human NK cells. J Immunol. 2005;175(12):7996–8002. doi:10.4049/jimmunol.175.12.7996
   PubMed Web of Science ®Google Scholar